Literature DB >> 22678516

Impact of body mass index and tumor location on the incidence of benign histology at the time of nephron-sparing surgery.

Bruce R Kava1, Ahmed Eldefrawy, Rajinikanth Ayyathurai, Murugesan Manoharan, Mohamed Aziz, Vincent G Bird, Devendar Katkoori, Rajan Ramanathan, Merce Jorda, Gaetano Ciancio, Mark S Soloway, Raymond J Leveillee.   

Abstract

PURPOSE: Gender, smoking history, patient age, and tumor size have been found to impact the likelihood of benign histology at the time of nephron-sparing surgery (NSS). Providing external validation of these variables and evaluating the relationship between body mass index (BMI) and tumor location on the likelihood of benign histology during NSS for T1 tumors were the objectives of this study.
METHODS: Data were analyzed for consecutive patients undergoing NSS for T1 disease. Central tumors either were completely encircled by renal parenchyma, descended below the cortico-medullary junction, or were in direct opposition to the collecting system, renal sinus, or the hilar structures. Categorical variables were evaluated with chi-square test, and continuous variables were analyzed with independent sample t test. Logistic regression identified independent predictors of final pathology.
RESULTS: NSS was performed in 316 patients, of whom 79 (24 %) had benign tumors. Patients with benign tumors were more likely to be female, to have a lower BMI, and to have peripheral tumors. On multivariate analysis, female gender (hazard ratio, 3.97; 95 % CI, 2.92-4.53, p < 0.001), peripheral tumor location (hazard ratio, 2.27; 95 % CI, 1.73-3.21, p = 0.014), and lower BMI (hazard ratio, 1.5; 95 % CI, 1.12-1.94, p = 0.015) were independently associated with benign histopathology at the time of surgical resection.
CONCLUSIONS: Prospectively identifying which T1 tumors are benign would have tremendous implications for the patient. Ours is the first study that has identified the impact of tumor location and BMI on the risk of benign histology. Additional studies are needed to corroborate these findings and incorporate these data into future nomograms.

Entities:  

Mesh:

Year:  2012        PMID: 22678516     DOI: 10.1007/s11255-012-0207-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  26 in total

1.  Incidence of benign lesions according to tumor size in solid renal masses.

Authors:  Victor Srougi; Raphael B Kato; Fernanda A Salvatore; Pedro P M Ayres; Marcos F Dall'Oglio; Miguel Srougi
Journal:  Int Braz J Urol       Date:  2009 Jul-Aug       Impact factor: 1.541

2.  A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States).

Authors:  Keith T Flaherty; Charles S Fuchs; Graham A Colditz; Meir J Stampfer; Frank E Speizer; Walter C Willett; Gary C Curhan
Journal:  Cancer Causes Control       Date:  2005-11       Impact factor: 2.506

3.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women.

Authors:  Tone Bjørge; Steinar Tretli; Anders Engeland
Journal:  Am J Epidemiol       Date:  2004-12-15       Impact factor: 4.897

Review 5.  Prognostic models and algorithms in renal cell carcinoma.

Authors:  Brian R Lane; Michael W Kattan
Journal:  Urol Clin North Am       Date:  2008-11       Impact factor: 2.241

6.  Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma.

Authors:  Grégory Verhoest; Raffi Avakian; Karim Bensalah; Rodolphe Thuret; Vincenzo Ficarra; Walter Artibani; Jacques Tostain; François Guille; Lucas Cindolo; Alexandre De La Taille; Claude-Clément Abbou; Laurent Salomon; Nathalie Rioux-Leclercq; Jean-Jacques Patard
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

7.  Pathologic characteristics of solitary small renal masses: can they be predicted by preoperative clinical parameters?

Authors:  Tom DeRoche; Esteban Walker; Cristina Magi-Galluzzi; Ming Zhou
Journal:  Am J Clin Pathol       Date:  2008-10       Impact factor: 2.493

Review 8.  Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how?

Authors:  Mesut Remzi; Michael Marberger
Journal:  Eur Urol       Date:  2008-10-07       Impact factor: 20.096

9.  Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies.

Authors:  William T Lowrance; R Houston Thompson; David S Yee; Matthew Kaag; S Machele Donat; Paul Russo
Journal:  BJU Int       Date:  2009-07-06       Impact factor: 5.588

10.  Obesity and renal cell cancer--a quantitative review.

Authors:  A Bergström; C C Hsieh; P Lindblad; C M Lu; N R Cook; A Wolk
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

View more
  3 in total

Review 1.  Gender differences in benign renal masses.

Authors:  Julian Mauermann; Michela de Martino; Matthias Waldert; Andrea Haitel; Hans Christoph Klingler; Mesut Remzi; Tobias Klatte
Journal:  World J Urol       Date:  2013-02-16       Impact factor: 4.226

2.  Body mass index and comorbidity are associated with postoperative renal function after nephrectomy.

Authors:  Lael Reinstatler; Zachary Klaassen; Brittani Barrett; Martha K Terris; Kelvin A Moses
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

3.  Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study.

Authors:  Naveen Nandanan; Alessandro Veccia; Alessandro Antonelli; Ithaar Derweesh; Alexandre Mottrie; Andrea Minervini; Monish Aron; Giuseppe Simone; Umberto Capitanio; Claudio Simeone; Daniel Eun; Sisto Perdonà; James Porter; Chandru Sundaram; Chao Zhang; Robert Uzzo; Ben Challacombe; Lance J Hampton; Jihad Kaouk; Francesco Porpiglia; Riccardo Autorino
Journal:  Cent European J Urol       Date:  2020-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.